Rezaei Yousef, Gholami-Fesharaki Mohammad, Dehghani Mohammad Reza, Arya Arash, Haghjoo Majid, Arjmand Nasim
Seyyed-al-Shohada Heart Center, Urmia University of Medical Science, Urmia, Iran
Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
J Cardiovasc Pharmacol Ther. 2016 Mar;21(2):167-76. doi: 10.1177/1074248415602557. Epub 2015 Sep 1.
Statin therapy has been thought to improve outcomes in cardiac surgeries. We aimed to determine the statin effects on the development of postoperative atrial fibrillation (AF), hospital length of stay (LOS), and inflammatory status in patients undergoing cardiac surgeries.
A systematic literature search in databases was performed, until January 2015. Randomized clinical trial (RCT) studies evaluating statin effect on statin-naive patients with sinus rhythm undergoing cardiac surgeries were eligible to be analyzed.
Twelve RCTs involving 1116 patients, 559 receiving statin and 557 receiving control regimen, were analyzed. Postoperative AF occurred in 17.9% and 36.1% of patients in the statin and control groups, respectively. The statin therapy was associated with decreases in the postoperative AF (risk ratio [RR] 0.50, 95% confidence interval [CI] 0.41-0.61, P < .000010), hospital LOS (mean difference in days, RR -0.44, 95% CI -0.67 to -0.20, P = .0002), and postoperative C-reactive protein (CRP) compared with control (mean difference in mg/L, RR -12.37, 95% CI -23.87 to -0.87, P = .04). The beneficial effects on AF and CRP were more marked in patients receiving atorvastatin compared to other statins. Decrease in postoperative AF was greater in coronary artery bypass graft surgery compared to that in isolated valvular surgery.
Perioperative statin therapy in statin-naive patients with sinus rhythm undergoing cardiac surgeries was associated with decreases in the development of postoperative AF, the hospital LOS, and the CRP level. However, there were insufficient data to provide evidences regarding statin impacts in patients undergoing isolated valvular surgery.
他汀类药物治疗被认为可改善心脏手术的预后。我们旨在确定他汀类药物对心脏手术患者术后房颤(AF)的发生、住院时间(LOS)和炎症状态的影响。
截至2015年1月,我们在数据库中进行了系统的文献检索。评估他汀类药物对未服用过他汀类药物且窦性心律的心脏手术患者影响的随机临床试验(RCT)研究符合分析条件。
分析了12项RCT,涉及1116例患者,其中559例接受他汀类药物治疗,557例接受对照治疗。他汀类药物组和对照组患者术后房颤的发生率分别为17.9%和36.1%。与对照组相比,他汀类药物治疗与术后房颤发生率降低(风险比[RR]0.50,95%置信区间[CI]0.41 - 0.61,P <.000010)、住院LOS缩短(天数的平均差异,RR -0.44,95% CI -0.67至-0.20,P =.0002)以及术后C反应蛋白(CRP)降低相关(mg/L的平均差异,RR -12.37,95% CI -23.87至-0.87,P =.04)。与其他他汀类药物相比,阿托伐他汀对房颤和CRP的有益作用更显著。与单纯瓣膜手术相比,冠状动脉旁路移植手术中术后房颤的降低幅度更大。
在未服用过他汀类药物且窦性心律的心脏手术患者中,围手术期他汀类药物治疗与术后房颤发生率降低、住院LOS缩短和CRP水平降低相关。然而,关于他汀类药物对单纯瓣膜手术患者影响的数据不足,无法提供相关证据。